Watch this webinar recording to learn how LIBRA-seq:
- Gives researchers broad access to study and leverage the human body’s antibody diversity for vaccine and immunotherapy development
- Accelerates discovery of novel antibody-antigen interactions by screening for multiple antigens in one assay
- Enables production of recombinant antibodies by pairing heavy- and light-chain full-length antibody sequences at the single cell level
- Demonstrates the power of integrating next-generation sequencing with standard immunology research techniques